This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Investigating the phase III results from the ANCHOR clinical trials on depemokimab in chronic rhinosinusitis with nasal polyps.

Ticker(s): GSK

Who's the expert?

Institution: Scripps Clinic

  • Allergist/Immunologist & Director, Aspirin Exacerbated Respiratory Disease Clinic,Division of Allergy, Asthma and Immunology at the Scripps Clinic.
  • Currently manages 35 patients with systemic mastocytosis.
  • Focus is on Aspirin exacerbated respiratory disease (AERD), mastocytosis, and mast cell activation syndromes; conducts research on aspirin exacerbated respiratory disease, a topic on which he has authored multiple publications and ongoing research protocols.

Interview Questions
Q1.

What are the current treatments available for chronic rhinosinusitis with nasal polyps, and how do you determine the progression from first-line to third-line treatment options?

Added By: catalin_admin
Q2.

How do you manage patients who do not respond well to a biologic like Dupixent, and when do you consider switching biologics or opting for surgery?

Added By: catalin_admin
Q3.

What factors influence the choice of biologics, and how do you address patient concerns about injection frequency, cost, or needle anxiety?

Added By: catalin_admin
Q4.

How does depemokimab compare to other biologics like Dupixent or omalizumab in terms of mechanism, efficacy, and the six-month dosing schedule?

Added By: catalin_admin
Q5.

What are the key safety concerns, side effects, and insurance coverage challenges associated with biologics, including new treatments like depemokimab?

Added By: catalin_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.